Table 2.
Volume of admissions and procedures for genitourinary toxicity amongst included prostate cancer patients treated with primary prostate radiotherapy
| Outcome | Overall, N = 25451 | Date of radiotherapy | p value2 | |
|---|---|---|---|---|
| 1. < 2009, N = 17811 | 2. ≥ 2009, N = 7641 | |||
| GU toxicity admission | 2545/2545 (100%) | 1781/1781 (100%) | 764/764 (100%) | |
| Admission category | 0.39 | |||
| 1. Elective | 1505/2545 (59%) | 1063/1781 (60%) | 442/764 (58%) | |
| 2. Emergency | 1040/2545 (41%) | 718/1781 (40%) | 322/764 (42%) | |
| GU toxicity readmission | 1893/2545 (74%) | 1364/1781 (77%) | 529/764 (69%) | < 0.001 |
| Healthcare sector | < 0.001 | |||
| Private | 231/2545 (9.1%) | 135/1781 (7.6%) | 96/764 (13%) | |
| Public | 2314/2545 (91%) | 1646/1781 (92%) | 668/764 (87%) | |
| Length of stay, mean (SD) | 4.76 (9.96) | 4.59 (9.64) | 5.13 (10.65) | 0.24 |
| Haematuria | 1509/2545 (59%) | 1049/1781 (59%) | 460/764 (60%) | 0.54 |
| Obstruction | 1045/2545 (41%) | 753/1781 (42%) | 292/764 (38%) | 0.056 |
| Incontinence | 355/2545 (14%) | 251/1781 (14%) | 104/764 (14%) | 0.75 |
| No procedure | 1402/2545 (55%) | 934/1781 (52%) | 468/764 (61%) | < 0.001 |
| Non-operative procedure | 106/2545 (4.2%) | 83/1781 (4.7%) | 23/764 (3.0%) | 0.056 |
| Minor operative procedure | 1044/2545 (41%) | 769/1781 (43%) | 275/764 (36%) | < 0.001 |
| Major operative procedure | 57/2545 (2.2%) | 41/1781 (2.3%) | 16/764 (2.1%) | 0.75 |
| Diagnostic cystoscopy | 701/2545 (28%) | 499/1781 (28%) | 202/764 (26%) | 0.41 |
| Urethral dilation | 198/2545 (7.8%) | 152/1781 (8.5%) | 46/764 (6.0%) | 0.030 |
| Cystoscopic washout | 157/2545 (6.2%) | 111/1781 (6.2%) | 46/764 (6.0%) | 0.84 |
| Ureteric stent procedure | 101/2545 (4.0%) | 84/1781 (4.7%) | 17/764 (2.2%) | 0.003 |
| Suprapubic catheter | 70/2545 (2.8%) | 62/1781 (3.5%) | 8/764 (1.0%) | < 0.001 |
| Antegrade percutaneous procedure | 17/2545 (0.7%) | 15/1781 (0.8%) | 2/764 (0.3%) | 0.10 |
| TURBT | 27/2545 (1.1%) | 20/1781 (1.1%) | 7/764 (0.9%) | 0.64 |
| Bladder repair | 11/2545 (0.4%) | 4/1781 (0.2%) | 7/764 (0.9%) | 0.021 |
| Urinary diversion | 6/2545 (0.2%) | 6/1781 (0.3%) | 0/764 (0%) | 0.19 |
| Ureteric dilation | 7/2545 (0.3%) | 5/1781 (0.3%) | 2/764 (0.3%) | > 0.99 |
| Artificial urinary sphincter | 5/2545 (0.2%) | 5/1781 (0.3%) | 0/764 (0%) | 0.33 |
| Ureteric reimplantation | 1/2545 (< 0.1%) | 1/1781 (< 0.1%) | 0/764 (0%) | > 0.99 |
Any statistically significant p-values were bolded
GU, Genitourinary; LOS, Length of stay; TURBT, Transurethral Resection of Bladder Tumour
1n/N (%); Mean(SD)
2Pearson’s Chi-squared test; Wilcoxon rank sum test; Fisher’s exact test